

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A composition comprising at least one oligonucleotide in an emulsion and a bile salt, wherein said bile salt is selected from the group consisting of ~~cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid, taurodeoxycholic acid, chenodeoxycholic acid, ursodeoxycholic acid, sodium-tauro-24,25-dihydrofusidate, sodium-glycodehydrofusidate, polyoxyethylene-9-lauryl ether~~ and a pharmaceutically acceptable salt thereof, and a combination thereof; and a fatty acid, wherein the emulsion provides enhanced bioavailability of the oligonucleotide as compared to oligonucleotide delivered without penetration enhancer.

2-3. (cancelled).

4. (previously presented) The composition of claim 1 wherein said oligonucleotide is a ribozyme or a peptide nucleic acid.

5. (original) The composition of claim 1 wherein said emulsion is selected from the group consisting of an oil-in-water emulsion, a water-in-oil emulsion, an oil-in-water-in-oil emulsion, and a water-in-oil-in water emulsion.

6. (original) The composition of claim 1 wherein said emulsion is a microemulsion.

7. (previously presented) The composition of claim 6 wherein said microemulsion is selected from the group consisting of an oil-in-water microemulsion, a water-in-oil microemulsion, an oil-in-water-in-oil microemulsion, and a water-in-oil-in water microemulsion.

8-18. (cancelled).

19. (original) The composition of claim 1 further comprising at least one carrier compound.

20. (previously presented) The composition of claim 19 wherein said carrier compound is selected from the group consisting of polyinosinic acid, dextran sulfate, polycytidic acid, and 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid.

21-79. (cancelled).

80. (previously presented) The composition according to claim 1, wherein said oligonucleotide comprises SEQ ID NO: 1.

81-83. (cancelled).

84. (previously presented) The composition of claim 1 wherein said emulsion is an oil-in-water-in-oil emulsion or a water-in-oil-in-water emulsion.

85. (previously presented) The composition according to claim 1, wherein said oligonucleotide is selected from the group consisting of SEQ ID NOS: 2, 48, 49, 50, 16, 19, 51, 52, 53, and 54.

86-90. (Cancelled).

91. (previously presented) The composition of claim 1 in dosage form suitable for nonparenteral administration.

92-94. (cancelled).

95. (previously presented) The composition of claim 1 in oral dosage form.

96. (cancelled).

97. (new) The composition of claim 1, wherein said fatty acid is caprate or a pharmaceutically acceptable salt thereof.